Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery.

J Pharm Bioallied Sci · 2015 · PMC4399007 · PMID 25883513

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Thus, the contribution of serotonin type-3 receptor and sub-types in the management of psychological disorders is quite significant.[ 3 ] The pharmacological activity of various drugs with 5-HT 3 receptor antagonistic activity has also been evaluated for generalized anxiety disorders or comorbid anxieties, which are being commercially available for nonpsychological disorders such as antiemetics, prokinetics.[ 3 ] In example, on

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.